228 related articles for article (PubMed ID: 12535574)
1. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.
Lin JH
Adv Drug Deliv Rev; 2003 Jan; 55(1):53-81. PubMed ID: 12535574
[TBL] [Abstract][Full Text] [Related]
2. Role of P-glycoprotein in pharmacokinetics: clinical implications.
Lin JH; Yamazaki M
Clin Pharmacokinet; 2003; 42(1):59-98. PubMed ID: 12489979
[TBL] [Abstract][Full Text] [Related]
3. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
4. Psychotropic drug-drug interactions involving P-glycoprotein.
Akamine Y; Yasui-Furukori N; Ieiri I; Uno T
CNS Drugs; 2012 Nov; 26(11):959-73. PubMed ID: 23023659
[TBL] [Abstract][Full Text] [Related]
5. Drugs as P-glycoprotein substrates, inhibitors, and inducers.
Kim RB
Drug Metab Rev; 2002; 34(1-2):47-54. PubMed ID: 11996011
[No Abstract] [Full Text] [Related]
6. Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice.
Miyake T; Tsutsui H; Haraya K; Tachibana T; Morimoto K; Takehara S; Ayabe M; Kobayashi K; Kazuki Y
Br J Pharmacol; 2021 Nov; 178(21):4335-4351. PubMed ID: 34232502
[TBL] [Abstract][Full Text] [Related]
7. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
8. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
[TBL] [Abstract][Full Text] [Related]
9. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
Ito K; Kusuhara H; Sugiyama Y
Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein.
Hochman JH; Yamazaki M; Ohe T; Lin JH
Curr Drug Metab; 2002 Jun; 3(3):257-73. PubMed ID: 12083320
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.
Fromm MF
Int J Clin Pharmacol Ther; 2000 Feb; 38(2):69-74. PubMed ID: 10706193
[TBL] [Abstract][Full Text] [Related]
12. P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions.
Kumar YS; Adukondalu D; Sathish D; Vishnu YV; Ramesh G; Latha AB; Reddy PC; Sarangapani M; Rao YM
Drug Metabol Drug Interact; 2010; 25(1-4):3-16. PubMed ID: 21417789
[TBL] [Abstract][Full Text] [Related]
13. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
Suzuki K; Taniyama K; Aoyama T; Watanabe Y
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
[TBL] [Abstract][Full Text] [Related]
15. Xanthones as P-glycoprotein modulators and their impact on drug bioavailability.
Silva V; Gil-Martins E; Silva B; Rocha-Pereira C; Sousa ME; Remião F; Silva R
Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):441-482. PubMed ID: 33283552
[No Abstract] [Full Text] [Related]
16. Modulation of expression/function of intestinal P-glycoprotein under disease states.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):59-78. PubMed ID: 31821048
[No Abstract] [Full Text] [Related]
17. An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.
Han LW; Gao C; Mao Q
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):817-829. PubMed ID: 30010462
[TBL] [Abstract][Full Text] [Related]
18. The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
Li M; de Graaf IA; van de Steeg E; de Jager MH; Groothuis GM
Toxicol In Vitro; 2017 Apr; 40():26-33. PubMed ID: 27939799
[TBL] [Abstract][Full Text] [Related]
19. Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.
Elmeliegy M; Vourvahis M; Guo C; Wang DD
Clin Pharmacokinet; 2020 Jun; 59(6):699-714. PubMed ID: 32052379
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
